Fig 1: IL-37 suppresses M1 macrophage polarization and pro-inflammatory cytokines secretion. PMA-treated THP-1 cells were treated with LPS (100 ng/ml) and IFN-? (20 ng/ml) in the presence or absence of recombinant IL-37 (0.1 ng/ml). (A,B) Representative immunoblots and densitometric data show that IL-37 inhibits iNOS and CD11c expression; n = 3, *P < 0.05. (C,D) Representative immunoblots and densitometric data show that IL-37 down-regulates MCP-1 and IL-6 expression; n = 3, *P < 0.05. (E,F) The ELISA data show that IL-37 down-regulates MCP-1 and IL-6 secretion; n = 3, *P < 0.05, ***P < 0.001.
Fig 2: IL-37 modulates macrophage polarization through suppressing activation of the Notch1- NF-?B pathway axis. (A) Representative immunoblots and densitometric data show that stimulation with LPS and IFN-? enhances Notch1 pathway activation in PMA-treated THP-1 cells; n = 3, *P < 0.05, **P < 0.01. (B,C) PMA-treated THP-1 cells were treated with DAPT (50 µM) 1 h prior to LPS (100 ng/ml) and IFN-? (20 ng/ml) for 4–24 h. (B) Representative immunoblots show that DAPT inhibits Notch1 activation; n = 3. (C) Representative immunoblots and densitometric data show that Notch1 pathway inhibition reduces iNOS expression in M1 macrophages; n = 3, *P < 0.05. (D) PMA-treated THP-1 cells were treated with recombinant human IL-37 (0.1 ng/ml) 1 h prior to being treated with LPS (100 ng/ml) and IFN-? (20 ng/ml) at different times. Representative immunoblots and densitometric data show that IL-37 decreases NICD1 expression at different time point in M1 macrophages; n = 3. *P < 0.05 vs. corresponding control, §P < 0.05 vs. M1 macrophages treated with IL-37. (E) Representative immunoblots show that Notch1 pathway inhibition decreases NF-?B phosphorylation; n = 3.
Fig 3: Gene transfection of IL-37 in two liver cancer cell lines changes the protein expression of IL-37 and NF-?B through immunofluorescence staining. (A) Immunofluorescence staining for IL-37 and NF-?B in HepG2 cells. (B) Immunofluorescence staining for IL-37 and NF-?B in MHCC97H cells. Magnification, ×40. Scale bar, 10 µm. IL-37 group, cells transfected with IL-37 overexpressing plasmid pEZ-M02-IL-37; Control group, cells transfected with the control plasmid, pEZ-M02.
Fig 4: IL-37 and NF-?B protein expression in HCC and paracancerous tissues. (A) IL-37 expression in HCC tissues. (B) IL-37 expression in paracancerous tissues. (C) NF-?B expression in HCC tissues. (D) NF-?B expression in paracancerous tissues. Scale bar, 60 µm. HCC, hepatocellular carcinoma.
Fig 5: IL-37 promotes the expression of M2 macrophage markers.(A) Representative immunoblots and densitometric data show that CD206 expression increases after pre-treating PMA-treated THP-1 cells with recombinant human IL-37 (0.1 ng/ml) prior to stimulating with LPS (100 ng/ml) and IFN-? (20 ng/ml); n = 3, *P < 0.05. (B) The ELISA data show that IL-37 up-regulates IL-10 secretion; n = 4, **P < 0.01, ***P < 0.001.
Supplier Page from Abcam for Anti-IL37 antibody